Research published by two teams of Army scientists and collaborators has identified a cellular protein that plays a critical role in Ebola virus infection.

AVI BioPharma, Inc. (Nasdaq:AVII) announced today the presentation of data from two studies evaluating the company's NEUGENE® PLUS therapeutic antisense compounds in the treatment of nonhuman primates (NHP) exposed to the Ebola virus.